Shijiazhuang

Researchers are evaluating the real-world effectiveness of mavacamten treatment in Chinese adults who have symptomatic obstructive hypertrophic cardiomyopathy (HCM). This study focuses on adults aged 18 years or older diagnosed with obstructive HCM, following established clinical guidelines. It aims to assess changes in heart function, particularly the left ventricular outflow tract (LVOT) gradient, over time during treatment with mavacamten. Participants will receive mavacamten according to the product label. The study includes both patients who have already started mavacamten and those scheduled to begin treatment. Key follow-up visits are planned at weeks 4, 8, 12, 24, 36, 48, 72, and 96 to monitor treatment effects. The main outcomes measured are changes in the LVOT gradient at weeks 48 and 96, reflecting heart function improvements. During the study, participants will undergo regular assessments, including echocardiograms to measure heart function, documentation of symptoms using the New York Heart Association (NYHA) classification, and tracking of medication dosage. Essential medical information from recent records will be collected, and safety monitoring will continue throughout the 96-week follow-up period. The study aims to gather comprehensive data on mavacamten's impact on heart function and symptom improvement in this patient population.